STO:HNSA

Hansa Biopharma AB (publ) · STO · Healthcare · SEK · FY for 2025

Figures on this page computed 2026-11-08 12:41 UTC

Last close

n/aSEK

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
SEK
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-240.3%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
-247.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SEK
- computed

Price is the furthest below its sector's middle: 0.09 against 0.31 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

3.02x

1.15x

1.35x

2.51x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales3.02x
Its own average over 10 years, 73.5M.
Profit1.15x
Its own average over 10 years, -464.9M.
Free cash flow1.35x
Its own average over 10 years, -405.4M.
Debt2.51x
Its own average over 10 years, 372.2M.
Pricen/a
Its own average over 0 years. Market data

Sales is furthest from its own average, at 3.02 times.

Sales is 3.02 times its own 10-year average; Profit is 1.15 times its own 10-year average; Free cash flow is 1.35 times its own 10-year average; Debt is 2.51 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average3.02
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Profit against its own 10-year average1.15
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Free cash flow against its own 10-year average1.35
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Debt against its own 10-year average2.51
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
SEK